IL17A and metabolic syndrome: Other studies suggest that IL-17 may have a more dominant role in linking psoriasis with MetS, particularly in its systemic effects, while IL-23 primarily supports Th17 cell activity without directly driving psoriasis or metabolic dysfunction [22].